Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

Sponsor
Sanofi
Study ID
NCT07052396
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.

Study Details

Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.

Key Dates

Start date
Jul 1, 2025
Status verified
Dec 2025
Primary completion
Jul 1, 2029
Completion
Jul 1, 2029

Study Design

Enrollment
350 participants (estimated)

Primary Outcome Measure

Change from Baseline in COPD Assessment Test (CAT) Score [ Time Frame: Baseline up to 12 months ]

Central Contacts

  • Trial Transparency email recommended (Toll free for US & Canada)
    800-633-1610
    [email protected]

Related Studies